BACKGROUND: Pim kinases are constitutively active serine/threonine/tyrosine kinases that are overexpressed in hematological malignancies such as multiple myeloma. Pim kinase substrates are involved in transcription, protein translation, cell proliferation, and apoptosis. SGI-1776 is a potent Pim kinase inhibitor that has proven to be cytotoxic to leukemia and lymphoma cells. Based on this background, we hypothesized that SGI-1776 treatment would result in myeloma cytotoxicity. MATERIALS AND METHODS: To test this, myeloma cell lines and primary CD138(+) cells from myeloma patients were treated with SGI-1776 in a dose- and time-dependent manner, and effect on cell death and proliferation, induction of autophagy, and changes in cell cycle profile were measured. RESULTS: SGI-1776 treatment resulted in limited apoptosis in cell lines (mean 30%) and CD138(+) cells (< 10%) assessed using Annexin-V/propidium iodide. Limited effect was observed in cell cycle profile or growth in cell lines. However, DNA synthesis was decreased by 70% at 3 μM (all time points) in U266 though this was not observed in MM.1S. In accordance, immunoblot analyses revealed no change in transcription (c-Myc and H3), or apoptotic (Bad) proteins that are substrates of Pim kinases. In contrast, autophagy, assessed using acridine orange staining, was induced with SGI-1776 treatment in both cell lines (U266, 25%-70%; MM.1S, 8%-52%) and CD138(+) cells (19%-21%). Immunoblot analyses of the autophagy LC3b marker and translation initiation proteins (phospho-p70S6K and 4E-BP1) corroborated autophagy induction. CONCLUSION: These data indicate that SGI-1776 treatment in myeloma cell lines and CD138(+) myeloma cells elicits its deleterious effects through inhibition of translation and induction of autophagy.
BACKGROUND:Pim kinases are constitutively active serine/threonine/tyrosine kinases that are overexpressed in hematological malignancies such as multiple myeloma. Pim kinase substrates are involved in transcription, protein translation, cell proliferation, and apoptosis. SGI-1776 is a potent Pim kinase inhibitor that has proven to be cytotoxic to leukemia and lymphoma cells. Based on this background, we hypothesized that SGI-1776 treatment would result in myelomacytotoxicity. MATERIALS AND METHODS: To test this, myeloma cell lines and primary CD138(+) cells from myelomapatients were treated with SGI-1776 in a dose- and time-dependent manner, and effect on cell death and proliferation, induction of autophagy, and changes in cell cycle profile were measured. RESULTS:SGI-1776 treatment resulted in limited apoptosis in cell lines (mean 30%) and CD138(+) cells (< 10%) assessed using Annexin-V/propidium iodide. Limited effect was observed in cell cycle profile or growth in cell lines. However, DNA synthesis was decreased by 70% at 3 μM (all time points) in U266 though this was not observed in MM.1S. In accordance, immunoblot analyses revealed no change in transcription (c-Myc and H3), or apoptotic (Bad) proteins that are substrates of Pim kinases. In contrast, autophagy, assessed using acridine orange staining, was induced with SGI-1776 treatment in both cell lines (U266, 25%-70%; MM.1S, 8%-52%) and CD138(+) cells (19%-21%). Immunoblot analyses of the autophagy LC3b marker and translation initiation proteins (phospho-p70S6K and 4E-BP1) corroborated autophagy induction. CONCLUSION: These data indicate that SGI-1776 treatment in myeloma cell lines and CD138(+) myeloma cells elicits its deleterious effects through inhibition of translation and induction of autophagy.
Authors: Kevin R Kelly; Claudia M Espitia; Pietro Taverna; Gavin Choy; Swaminathan Padmanabhan; Steffan T Nawrocki; Francis J Giles; Jennifer S Carew Journal: Br J Haematol Date: 2011-06-21 Impact factor: 6.998
Authors: J Asano; A Nakano; A Oda; H Amou; M Hiasa; K Takeuchi; H Miki; S Nakamura; T Harada; S Fujii; K Kagawa; I Endo; K Yata; A Sakai; S Ozaki; T Matsumoto; M Abe Journal: Leukemia Date: 2011-04-08 Impact factor: 11.528
Authors: Shannon M Mumenthaler; Patricia Y B Ng; Amanda Hodge; David Bearss; Gregory Berk; Sarath Kanekal; Sanjeev Redkar; Pietro Taverna; David B Agus; Anjali Jain Journal: Mol Cancer Ther Date: 2009-10 Impact factor: 6.261
Authors: D Mahalingam; C M Espitia; E C Medina; J A Esquivel; K R Kelly; D Bearss; G Choy; P Taverna; J S Carew; F J Giles; S T Nawrocki Journal: Br J Cancer Date: 2011-10-20 Impact factor: 7.640
Authors: Yong Xu; Benjamin G Brenning; Steven G Kultgen; Jason M Foulks; Adrianne Clifford; Shuping Lai; Ashley Chan; Shannon Merx; Michael V McCullar; Steven B Kanner; Koc-Kan Ho Journal: ACS Med Chem Lett Date: 2014-10-22 Impact factor: 4.345
Authors: Marc S Raab; Sheeba K Thomas; Enrique M Ocio; Andreas Guenther; Yeow-Tee Goh; Moshe Talpaz; Nicolas Hohmann; Sylvia Zhao; Fang Xiang; Carl Simon; K Gary Vanasse; Shaji K Kumar Journal: Leukemia Date: 2019-05-15 Impact factor: 11.528
Authors: Neha S Bhise; Lata Chauhan; Miyoung Shin; Xueyuan Cao; Stanley Pounds; Vishal Lamba; Jatinder K Lamba Journal: Front Pharmacol Date: 2016-01-28 Impact factor: 5.810